ASTRA MERCK ROFLEPONIDE ASTHMA STEROID TO FILL MILD/PEDIATRIC ASTHMA NICHE, ASTRA SAYS; PULMICORT/OXIS COMBO TRIALS IN 2,000 PATIENTS "ABOUT TO START"
Astra's next inhaled steroid project, rofleponide, will be especially useful for children and mild asthmatics, Astra Draco VP-Clinical R&D Anders Ullman suggested during a Jan. 22 meeting with financial analysts in London.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth